CA3243435A1 - TREATMENT METHODS USING THE P-TAU181 LEVEL - Google Patents
TREATMENT METHODS USING THE P-TAU181 LEVELInfo
- Publication number
- CA3243435A1 CA3243435A1 CA3243435A CA3243435A CA3243435A1 CA 3243435 A1 CA3243435 A1 CA 3243435A1 CA 3243435 A CA3243435 A CA 3243435A CA 3243435 A CA3243435 A CA 3243435A CA 3243435 A1 CA3243435 A1 CA 3243435A1
- Authority
- CA
- Canada
- Prior art keywords
- subject
- months
- level
- dose
- protofibril antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Psychiatry (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263306060P | 2022-02-02 | 2022-02-02 | |
| US63/306,060 | 2022-02-02 | ||
| US202263269394P | 2022-03-15 | 2022-03-15 | |
| US63/269,394 | 2022-03-15 | ||
| US202263364617P | 2022-05-12 | 2022-05-12 | |
| US63/364,617 | 2022-05-12 | ||
| PCT/US2022/079571 WO2023149970A1 (en) | 2022-02-02 | 2022-11-09 | Methods of treatment using p-tau181 level |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3243435A1 true CA3243435A1 (en) | 2023-08-10 |
Family
ID=84488881
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3243435A Pending CA3243435A1 (en) | 2022-02-02 | 2022-11-09 | TREATMENT METHODS USING THE P-TAU181 LEVEL |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250377367A1 (https=) |
| EP (1) | EP4473009A1 (https=) |
| JP (1) | JP2025506389A (https=) |
| KR (1) | KR20240142535A (https=) |
| AU (1) | AU2022439338A1 (https=) |
| CA (1) | CA3243435A1 (https=) |
| CL (1) | CL2024002309A1 (https=) |
| IL (1) | IL314581A (https=) |
| MX (1) | MX2024009492A (https=) |
| TW (1) | TW202339794A (https=) |
| WO (1) | WO2023149970A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025260029A1 (en) * | 2024-06-14 | 2025-12-18 | Eisai R&D Management Co., Ltd. | Method for quantifying amyloid beta protofibril |
| CN118777453B (zh) * | 2024-06-25 | 2025-04-08 | 上海交通大学医学院附属瑞金医院 | 一种基于液相色谱-串联质谱定量分析血液中仑卡奈单抗浓度的方法 |
| WO2026015877A1 (en) | 2024-07-12 | 2026-01-15 | Eisai R&D Management Co., Ltd. | Fluid biomarker |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2414772C (en) | 2000-07-07 | 2011-06-28 | Jan Naslund | Prevention and treatment of alzheimer's disease |
| SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| RU2429244C2 (ru) | 2006-03-23 | 2011-09-20 | Байоарктик Ньюросайенс Аб | Улучшенные селективные в отношении протофибрилл антитела и их применение |
| LT2448968T (lt) | 2009-06-29 | 2021-05-10 | Bioarctic Ab | Antikūnai, atpažįstantys n gale sutrumpintas amiloido protofibriles/oligomerus |
| JP5894939B2 (ja) | 2010-02-26 | 2016-03-30 | バイオアークティック ニューロサイエンス アーベー | プロトフィブリル結合抗体ならびにパーキンソン病、レビー小体型認知症および他のα−シヌクレイノパチーの治療および診断方法におけるこれらの使用 |
| WO2016005466A2 (en) | 2014-07-10 | 2016-01-14 | Bioarctic Neuroscience Ab | IMPROVED Aß PROTOFIBRIL BINDING ANTIBODIES |
| AU2018352308B2 (en) | 2017-10-16 | 2025-06-05 | Eisai R&D Management Co., Ltd. | Anti-tau antibodies and uses thereof |
| US20210324056A1 (en) * | 2018-07-24 | 2021-10-21 | Eisai R&D Management Co., Ltd. | Methods of treatment and prevention of alzheimer's disease |
| KR20220084095A (ko) * | 2019-10-22 | 2022-06-21 | 바이오젠 엠에이 인코포레이티드 | 알츠하이머병의 치료를 위한 항-베타-아밀로이드 항체 |
| RS67249B1 (sr) | 2020-03-20 | 2025-10-31 | Eisai R&D Man Co Ltd | Formulacije antitela visoke koncentracije protiv protofibrila amiloid beta peptida i metode njihove upotrebe |
-
2022
- 2022-11-09 AU AU2022439338A patent/AU2022439338A1/en active Pending
- 2022-11-09 CA CA3243435A patent/CA3243435A1/en active Pending
- 2022-11-09 IL IL314581A patent/IL314581A/en unknown
- 2022-11-09 WO PCT/US2022/079571 patent/WO2023149970A1/en not_active Ceased
- 2022-11-09 US US18/835,235 patent/US20250377367A1/en active Pending
- 2022-11-09 MX MX2024009492A patent/MX2024009492A/es unknown
- 2022-11-09 EP EP22822805.2A patent/EP4473009A1/en active Pending
- 2022-11-09 KR KR1020247029332A patent/KR20240142535A/ko active Pending
- 2022-11-09 TW TW111142860A patent/TW202339794A/zh unknown
- 2022-11-09 JP JP2024545951A patent/JP2025506389A/ja active Pending
-
2024
- 2024-07-31 CL CL2024002309A patent/CL2024002309A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2024002309A1 (es) | 2025-01-24 |
| KR20240142535A (ko) | 2024-09-30 |
| TW202339794A (zh) | 2023-10-16 |
| JP2025506389A (ja) | 2025-03-11 |
| US20250377367A1 (en) | 2025-12-11 |
| AU2022439338A1 (en) | 2024-08-15 |
| MX2024009492A (es) | 2024-08-09 |
| WO2023149970A1 (en) | 2023-08-10 |
| IL314581A (en) | 2024-09-01 |
| EP4473009A1 (en) | 2024-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250163135A1 (en) | Biomarkers for alzheimer's disease treatment | |
| US20250377367A1 (en) | Methods of treatment using p-tau181 level | |
| JP7676556B2 (ja) | 抗Ｎ３ｐＧｌｕアミロイドベータ抗体及びその使用 | |
| TW202019471A (zh) | 阿茲海默症之治療及預防方法 | |
| JP7792428B2 (ja) | 抗アミロイドベータ抗体及びその使用 | |
| IL263433B1 (en) | Methods for treating alzheimer's disease | |
| EP4626918A1 (en) | Methods of treatment using a tau pet level | |
| JP2024532438A (ja) | 抗Ａβプロトフィブリル抗体の皮下製剤及びその使用方法 | |
| CN117940773A (zh) | 用于阿尔茨海默病治疗的生物标记物 | |
| CN118786141A (zh) | 使用p-tau181水平的治疗方法 | |
| EP4724147A1 (en) | Methods of treatment using an anti-abeta protofibril antibody | |
| EA052116B1 (ru) | Антитела к бета-амилоидному пептиду n3pglu и варианты их применения | |
| WO2026075947A1 (en) | Dosing regimens for early alzheimer's disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20240726 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20240729 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20240729 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20241001 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241101 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241101 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241101 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED Effective date: 20250219 Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250219 Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W200 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST OR RESPONSE SUBMITTED ONLINE Effective date: 20250219 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20250703 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS Effective date: 20250703 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251031 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251031 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REGISTER A DOCUMENT REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260423 |